|
|
Volumn 8, Issue 3, 2011, Pages 244-247
|
|
The COPD pipeline X
|
|
Author keywords
alpha 1 antitrypsin; anti inflammatory; Antibiotics; autophagy; Bronchitxol; CAL263; Daliresp; fidaxomicin; GSK961081; losmapimod; New Drug Approvals in 2010; NVC 422; Omalizumab; p38 MAP kinase inhibitors; PUFA; R bambuterol; rivaroxban; rosuvastatin; SCH 527123; stem cell therapy; V85546
|
|
Indexed keywords
ALPHA 1 ANTITRYPSIN;
ANTIBIOTIC AGENT;
ANTIINFLAMMATORY AGENT;
BAMBUTEROL;
BRONCHODILATING AGENT;
CAL 263;
CARBAMAZEPINE;
ETANERCEPT;
FIDAXOMICIN;
FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE;
GSK 299423;
GSK 961081;
GSK299423;
GSK961081;
GYRASE INHIBITOR;
INDACATEROL;
LOSMAPIMOD;
MANNITOL;
METALLOPROTEINASE INHIBITOR;
NVC 422;
OLODATEROL;
OMALIZUMAB;
OMEGA 3 FATTY ACID;
ONBREZ;
PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;
RAPAMYCIN;
RIVAROXABAN;
ROFLUMILAST;
ROSIGLITAZONE;
ROSUVASTATIN;
SCH 527123;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
V 85546;
V85546;
ANTIBIOTIC THERAPY;
ARTICLE;
AUTOPHAGY;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG SAFETY;
DRY POWDER;
ESCHERICHIA COLI;
FOOD AND DRUG ADMINISTRATION;
FORCED EXPIRATORY VOLUME;
HUMAN;
INTENSIVE CARE UNIT;
MESENCHYMAL STEM CELL TRANSPLANTATION;
MOLECULAR LIBRARY;
MULTICENTER STUDY (TOPIC);
NONHUMAN;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PHASE 4 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
STAPHYLOCOCCUS AUREUS;
X RAY CRYSTALLOGRAPHY;
ANTI-BACTERIAL AGENTS;
ANTI-INFLAMMATORY AGENTS;
BRONCHODILATOR AGENTS;
DRUG APPROVAL;
DRUG DISCOVERY;
DRUG EVALUATION;
HUMANS;
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;
|
|
EID: 79957595354
PISSN: 15412555
EISSN: 15412563
Source Type: Journal
DOI: 10.3109/15412555.2011.576887 Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
